753,843,750 shares of common stock outstanding as of March 31, 2014
Common Stock Outstanding: 754,143,750 (as of 6/30/2015) Restricted Common Stock: 668,687,689(as of 6/30/2015)
20,000,000 preferred shares authorized
3,882,500 Preferred stock outstanding
Cancer.im Social Network
Cancer.im is full of articles and helpful resources! Here are some examples!
Some of the Cancer.im articles!
All of these and over 100+ Pages more can be found at http://Cancer.im
Reverse Split History for VIRA:
IMPN to VIRA: 1:500 and increase in A/S to 2 billion, July 2011
IPEI 1:2000 R/S 01/31/2008
IPRE 1:500 R/S 10/10/2006
SFLM 1:30 R/S 07/13/2004
Features of Our Platform
Viratech company website:
Based in Stockton, California, Viratech Corp. has created an open source biotech research and development platform. Viratech has created a unique platform leveraging the utility of social collaboration, which will allow cancer research the opportunity for the first time to become open sourced. This is accomplished by allowing our development partners the ability to protect, promote and produce their research in unified online collaboration hubs known as micro social networks. Viratech's open source platform has integrated several intellectual property tools which, by leveraging our social collaboration network, can give our development partners a new intellectual property mechanism, which will help in addressing the protection of Intellectual Property, promotion through collaboration in our protected open source platform, and commercial development of the products achieved through collaborative research.
Using this platform, Viratech members can protect their intellectual property, then use Viratech's micro social network as a utility to promote and crowdfund the research and development to produce the new technology. Cancer.im http://www.cancer.im
Through its experience-based search engine and technology, Cancer.im's goal is to become the primary resource on the web for people affected by cancer, for the purpose of making a difference in their own lives and the lives of others. Cancer.im's mission is to empower every cancer patient, regardless of their ability to pay, with the power to research their disease and to find, organize, and manage their own cancer support network. The goal of these support networks is to assist the patient in conserving needed energy by reducing the burden associated with their own daily trials and tribulations. Cancer.im will strive to convert this saved energy into a higher level of patient activity and a stronger determination to fight their disease.
Unlike other social networks, Cancer.im was designed by a team that is dedicated to specifically serve the unique needs of those currently struggling with the disease. This new network combines databases of medical community knowledge, repositories of wisdom from cancer survivors, systems for helping cancer patients organize their records and various facets of their treatment, and tools that allow patients and their supporters to work together effectively. In short, Cancer.im provides everything a cancer patient, friend, or family member is looking for to help in the fight against the disease, all in one online location and easy-to-use format.
Cancer.im technology can use its platforms and resources to help authors get book distribution through its patented ways to use social networks, copyright protection, and create new markets for eBooks.
Find and Stop Breast Cancer, Cancer.im's first in a series of books on Cancer, reaches number one best seller status (breast cancer) on Amazon.com
Cancer Patient's User Manual, another Best Seller.
Dr. Kevin Buckman - CEO and Director
Rachael Boulds - CFO
Matt Heindel- Director
Aziz Kamali, MD - Director
Valerie Kidd, MD - Director
Legal Counsel - Crawford S. Shaw
Corporate Counsel - Kenneth Eade
How many VIRA shares does Ken Eade still own??
According to an analyst report by Harbinger Research http://www.marketwire.com/press-release/harbinger-issues-special-situation-report-on-viratech-corp-vira-vira-1750160.htm
"Viratech has a scalable, well-designed technology system that should generate significant revenues from all three planned revenue channels. We believe its approach to using user-generated content to attract new members and its use of a point system to incentivize all members to both generate more content and invite other members is nothing short of genius. While the proof remains in the pudding, we believe Viratech has an excellent chance at executing on its business plan and creating a sea of change in the way social networking is applied to solving healthcare challenges globally, especially in complex fields such as cancer treatment and research. We are equally sanguine regarding Viratech's primary micro social networking model and its ability to create engagement funnels for a wide variety of individuals and companies. With the valuations of Facebook and LinkedIn running at an average of 13x trailing revenues, it is easy to see how even moderate business success could justify the Company's current valuation, and success of the caliber we anticipate will likely drive its shares significantly higher. Our Special Situation report does not include a rating or price target at this time, but we will be keeping a close watch on Viratech as it rolls out cancer.im next month, and suggest that all profit-minded investors do the same."
This report was prepared for informational purposes only. Harbinger Research, LLC ("Harbinger") was paid by Viratech Corporation ("Company") in the amount of US$21,800 for the preparation and distribution of a this special situation report, and for ongoing coverage for a period of one (1) year. All information contained in this report was provided by the Company. To ensure complete independence and editorial control over its research, Harbinger has developed various compliance procedures and business practices including but not limited to the following: (1) Fees from covered companies are due and payable prior to the commencement of research; (2) Harbinger, as a contractual right, retains complete editorial control over the research; (3) Analysts are compensated on a per-company basis and not on the basis of his/her recommendations; (4) Analysts are not permitted to accept fees or other consideration from the companies they cover for Harbinger except for the payments they receive from Harbinger; (5) Harbinger will not conduct investment banking or other financial advisory, consulting or merchant banking services for the covered companies.
Harbinger did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company is relying solely upon information provided by the companies for the accuracy and completeness of all such information. The information provided in the Report may become inaccurate upon the occurrence of material changes, which affect the Company and its business. Neither the Company nor Harbinger is under any obligation to update this report or ensure the ongoing accuracy of the information contained herein. This report does not constitute a recommendation or a solicitation to purchase or sell any security, nor does it constitute investment advice. This report does not take into account the investment objectives, financial situation or particular needs of any particular person. This report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Information about past performance of an investment is not necessarily a guide to, indicator of, or assurance of, future performance. Harbinger cannot and does not assess, verify or guarantee the adequacy, accuracy, or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. Harbinger and its clients, affiliates and employees, may, from time to time, have long or short positions in, buy or sell, and provide investment advice with respect to, the securities and derivatives (including options) thereof, of companies mentioned in this report and may increase or decrease those positions or change such investment advice at any time. Harbinger is not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
VIRATECH CORP ANNOUNCES THAT FRED SCHIEMANN HAS JOINED VIRATECH AS ITS NEW CEO
RENO, NEVADA /August 25, 2015 –Viratech, Corp. (OTC: VIRA), a software company focusing on developing disruptor based applications in the communication broadcasting, work flow management, crowd sourced labor and biotechnology fields. Viratech announced today that Fred Schiemann has joined Viratech as its new CEO.
Mr. Schiemann received his Bachelor of Science degree in accounting from the University of Illinois. He received his MS in Taxation from Golden Gate University. He currently is licensed as a Certified Public Accountant in Nevada.
“Viratech has now completed an extended phase of research and development for its proprietary software platform. The Company can now enter into the execution of business development agreements with entities looking to fully execute on our revenue sources available utilizing our proprietary software platform. I am excited that we have someone of Fred Schiemann’s experience as our new CEO,” stated Kevin Buckman former Viratech CEO and current Viratech Chief Medical Officer.
Mr. Schiemann has experience in the natural resource business, renewable energy, health sciences/medical, telecommunications and numerous other industries. He has experience in the investor relations industry and has numerous contacts in the broker/dealer community.
During his years of practice, his main areas of focus have been taxation, auditing and public securities work. He has been involved with many public registrations and structuring of mergers and acquisitions over the last twenty plus years. His emphasis is on public registrations, administration and consulting to small and micro-cap public companies.
Mr. Schiemann has assisted in the completion dozens of public offerings through reverse mergers and/or acquisitions, providing the necessary documentation for compliance as required by the regulatory agencies. His guidance and experience has helped companies raise millions of dollars in capital and he has built a reputation as a trusted professional.
VIRATECH CORP ANNOUNCES THAT DR.KEVIN BUCKMAN HAS BECOME ITS NEW CHIEF MEDICAL OFFICER
RENO, NEVADA /August 25, 2015 –Viratech, Corp. (OTC: VIRA), is a software company focusing on developing disruptor based applications in the communication broadcasting, work flow management, crowd sourced labor and biotechnology fields. The Company announced today that Kevin Buckman MD has become its new CMO (Chief Medical Officer). Dr. Buckman previously served as CEO of Viratech Corp.
“Four years ago Dr. Buckman had a vision in creating a software platform that could capture, interact and broadcast information in a unique way. Now that the computer software infrastructure is built, I am excited that Dr. Buckman will be our Chief Medical Officer in charge of all new Biotech applications of our new software platform” stated Fred Schiemann, Viratech’s new Chief Executive Officer.
Kevin Buckman MD, is a best-selling author on cancer, diabetes and cellular metabolism. He has over thirty nine years of Health Care Experience in a variety of areas of medicine, including research, diagnosis, and application of current medicine and other procedures. Dr. Buckman has presented research, published articles and books in the field of medicine, and has given lectures at numerous hospitals and at Medical Conferences in many different countries.
During the last thirty five years, he has worked to advance a number of medical technologies with a focus on Non-Harmful early detection of disease, with a primary focus on Breast Cancer, Diabetes and other auto-immune diseases. He is currently serving on the Industry Advisory Board for the University of Pacific School of Engineering and Computer Science and a Visiting Professor. He has decades of hospital Medical Director experience and has served on over many hospital committees for thirty five years and has served as Medical Director or Associate Director at Multiple Institutions.
About Viratech Corp.
Viratech is a software company focusing on developing disruptor based applications in the communication broadcasting, work flow management, crowd sourced labor and social media fields. To learn more about Viratech please visit www.viratech.org.
429 W. Plumb Lane Reno, NV 89509
CURRENT ON ALL FINANCIALS!
85 MIL FLOAT
ViraTech Subsidiary Cancer.im has Books on AMAZON $AMZN https://www.amazon.com/gp/search/ref=sr_nr_seeall_9?rh=k%3AKevin+Buckman+MD%2Ci%3Astripbooks&keywords=Kevin+Buckman+MD&ie=UTF8&qid=1445478275